COMPANY:

J&J

"BostonGene...today announced a strategic collaboration with Johnson & Johnson (Janssen Research & Development, LLC.), to address the most pressing challenge in multiple myeloma therapy: optimal sequencing of therapies to enable the safest and most effective treatment regimens."

"Abstract is embargoed at this time."

P3 | "Participants are randomized to one of two arms: ▪ Arm 1: Patients will continue on standard ADT + ARPI (abiraterone acetate with prednisone, apalutamide, enzalutamide, or darolutamide). SPL: Aura Bioscience, FKD, JBL (SWOG), Genentech (SWOG), Merck (Alliance), QED Therapeutics, Surge Therapeutics, Vaxiion, Viventia. Consultant/Advisory Board:Aura Bioscience, BMS, C2iGenomics, Ferring, Immunity Bio, Incyte, Gilead, Pfizer/EMD Serono, Protara, Surge Therapeutics, Tyra Biosciences, UroGen, Vaxiion, Verity; Patent – TCGA classifier; Honoraria – Grand Rounds Urology, UroToday"

"Recall the design of ongoing clinical trials evaluating other novel agents and strategies for prostate cancer, and appropriately counsel patients about availability and participation. Target Audience This activity is intended for medical oncologists, hematology-oncology fellows, urologists and other healthcare providers involved in the treatment of prostate cancer."

"Johnson & Johnson...announced today that new data from its leading oncology pipeline will be presented at the American Urological Association (AUA) 2025 Annual Meeting, taking place April 26-29 in Las Vegas. Among the highlights are the 12-month duration of response (DOR) data from the Phase 2b Cohort 2 SunRISe-1 study, evaluating TAR-200—an intravesical gemcitabine releasing system—for patients with Bacillus Calmette-Guérin (BCG)—unresponsive, high-risk non-muscle-invasive bladder cancer (HR-NMIBC) with carcinoma in situ (CIS) with or without papillary disease. These findings will be featured in the Practice-changing, Paradigm-shifting Clinical Trials in Urology plenary session on Saturday, April 26."

"Register now to join the experts in person or online and get the tools you need to provide optimal prostate cancer care. Key Reasons to Attend Hear expert analysis of the evidence supporting treatment intensification approaches across the disease spectrum Hone your ability to incorporate state-of-the art treatment regimens into patient-centric care Develop your toolbox of team-based strategies for improving therapeutic adherence through effective adverse event mitigation, management, and patient education This activity has been developed in partnership with ZERO Prostate Cancer."

P2 | "Ipi+nivo showed notable efficacy and impressive mDOR in pts with TMB/TML-H tumors across tumor types. Higher TMB/TML correlated with CB, offering further opportunities to refine patient selection."

"Illumina Inc...today announced it has signed an agreement with Janssen Research & Development, LLC (Janssen). This collaboration will be the first relating to the development of Illumina's novel molecular residual disease (MRD) assay, a whole-genome sequencing (WGS) multi-cancer research solution that detects circulating tumor DNA (ctDNA) to better understand the persistence or recurrence of disease following clinical intervention....The Illumina WGS MRD assay, which is currently in development, will detect ctDNA for MRD assessment in research settings that evaluate samples from patients previously diagnosed with cancer across multiple solid tumor indications."

"Diatech Pharmacogenetics ('Diatech') has established a collaboration agreement with Janssen Pharmaceutica NV with the aim of improving access to precision medicine for patients with bladder cancer."